RxDoctor Payments Data

Stephen Burke, MD

Family Medicine · West Sayville, NYNPI 1790733681

Payments from drug & device makers

$587in general payments, 2019–2025

Across 17 payments — averaging $34.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$212
  • Exact Sciences$142
  • Novo Nordisk$124
  • Lilly USA, LLC$76
  • Boston Scientific$19
  • Pfizer$13

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen5$212
Exact Sciences6$142
Novo Nordisk1$124
Lilly USA, LLC3$76
Boston Scientific1$19
Pfizer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$587 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$213,498
Medicare patients
687
Services billed
8,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$84,527
JanuviaSitagliptin Phosphate20$30,127
EntrestoSacubitril/Valsartan16$28,204
OzempicSemaglutide18$25,012
NuedextaDextromethorphan Hbr/Quinidine12$21,468
XareltoRivaroxaban19$20,991
FarxigaDapagliflozin Propanediol13$19,180
Breo ElliptaFluticasone/Vilanterol21$8,898
Atorvastatin Calcium442$4,993
Advair HfaFluticasone Propion/Salmeterol16$4,869
Metoprolol Succinate279$4,371
Albuterol Sulfate HfaAlbuterol Sulfate98$3,495
Rosuvastatin Calcium229$3,491
Levothyroxine Sodium167$2,523
SynthroidLevothyroxine Sodium34$2,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$84,527100 claims
Novo NordiskOzempic$124$25,01218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in West Sayville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →